Last checked at 
Braveheart Investment Group PLC - Dodworth, England-based investment company - Updates on Kirkstall Ltd, a company within its investment portfolio. Says Kirkstall, in conjunction with the Biomedical Ultrasonics, Biotherapy & Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at the University of Oxford, has developed an "organ on a chip" model of a milli-fluidic system, human blood-brain barrier which has been used to map the interaction between the blood-brain barrier and brain cancer. Explains this is the first time a dynamic milli-fluidic model has been developed where the interactions between the blood-brain barrier and medulloblastoma brain cancer spheroids have been demonstrated.
Braveheart holds an 86% equity interest in Kirkstall.
Current stock price: 12.19 pence, down 0.5% in London on Friday
12-month change: up 16%
By Heather Rydings, Alliance News senior economics reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
